Adalimumab, Infliximab, and Etanercept Biosimilars Global Market Report 2022 by The Business Research Company is the most comprehensive report available on the market, being wide-ranging both in terms of chronology and geography. It covers the historic period – 2016-2021, and the forecast period – 2022-2026, with additional forecasts for 2026-2031. The report helps gain a truly global perspective as it covers 60 geographies, focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
TBRC’s market
report includes a chapter on the COVID-19 impact on the adalimumab, infliximab,
and etanercept biosimilars industry, which gives valuable insights on supply
chain disruptions, logistical challenges, and other economic implications of
the virus on the market and how companies can strategize to bounce back from
it. With updated market numbers according to the effects of the coronavirus,
the report provides the most accurate expected adalimumab, infliximab, and
etanercept biosimilars market growth numbers from 2022-2031.
Request a Sample of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
The global adalimumab,
infliximab, and etanercept biosimilars market is expected to grow from $3.10
billion in 2021 to $4.76 billion in 2022 at a compound annual growth rate
(CAGR) of 53.4%. The growth in the market is mainly due to the companies
resuming their operations and adapting to the new normal while recovering from
the COVID-19 impact, which had earlier led to restrictive containment measures
involving social distancing, remote working, and the closure of commercial
activities that resulted in operational challenges. The adalimumab, infliximab
and etanercept biosimilar market is expected to reach $18.61 billion in 2026 at
a CAGR of 40.6%.
View more on the report:
The Adalimumab,
Infliximab, and Etanercept Biosimilars Global Market Report 2022-31 by The
Business Research Company evaluates adalimumab, infliximab, and etanercept
biosimilars market size, growth rate, drivers, adalimumab, infliximab, and
etanercept biosimilars industry trends, and major companies.
The adalimumab,
infliximab, and etanercept biosimilars market segments in the report are:
1) By Product:
Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others),
Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab
(Erelzi, Eticovo)
2) By Application:
Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis,
Ankylosing Spondylitis, Plaque Psoriasis, Others
3) By
Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The table of contents in TBRC’s adalimumab, infliximab, and etanercept
biosimilars market report includes:
1. Executive
Summary
2. Adalimumab,
Infliximab and Etanercept Biosimilars Market Characteristics
3. Adalimumab,
Infliximab and Etanercept Biosimilars Market Trends And Strategies
4. Impact Of
COVID-19 On Adalimumab, Infliximab and Etanercept Biosimilars
5. Adalimumab,
Infliximab and Etanercept Biosimilars Market Size And Growth.
.
28. Adalimumab,
Infliximab and Etanercept Biosimilars Pipeline Analysis
29. Key Mergers
And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars
Market
30. Adalimumab,
Infliximab and Etanercept Biosimilars Market Future Outlook and Potential
Analysis
31. Appendix
About The Business Research Company:
The Business
Research Company is a market intelligence firm that excels in company, market,
and consumer research. Located globally it has specialist consultants in a wide
range of industries including manufacturing, healthcare, financial services,
chemicals, and technology. It has offices in the UK, the US and India and
a network of trained researchers in 20+ countries globally.
Get a quick
glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
No comments:
Post a Comment